Based on these findings, the present study designed a drug screen based on the Otub1/c-Maf-driven luciferase and found that the antibiotic Nam can act as an inhibitor of the Otub1/c-Maf axis and it displays potent anti-MM activity in vitro and in vivo. This evidence concerns the gene MAF and Miyoshi myopathy.